The FDA refused to approve its use in combination with insulin for diabetes mellitus type 1 (T1DM), and phase III trials on SOTA in patients with T2DM and HF were regrettably and untimely terminated due to financial reasons and the COVID-19 pandemic. The gene discussed is INS; the disease is type 1 diabetes mellitus.